Research Summary

Thomas Hope, MD, is the Vice Chair of Clinical Operations and Strategy in the Department of Radiology. He also serves as the Director of Molecular Therapy. He serves as Chief of Nuclear Medicine at the San Francisco VA Medical Center and as chair of the Cancer Center’s Molecular Imaging & Radionuclide Therapy Site Committee. In 2007, he received his medical degree from Stanford University School of Medicine and he completed a one-year internship at Kaiser Permanente, San Francisco. From 2008-2012, Dr. Hope completed a residency in Diagnostic Radiology at the University of California, San Francisco, followed by a clinical fellowship in Body MRI and Nuclear Medicine from Stanford Medical Center in 2013.

Dr. Hope’s main research focus is on novel imaging agents and therapies, particularly in prostate cancer and neuroendocrine tumors. He lead the development of Ga-68 PSMA-11, which subsequently led to the approval of this drug by the FDA. He has combined his interest in MR imaging with PET in the simultaneous modality PET/MRI, helping lead the development of the clinical PET/MRI program. Additionally he leads the PRRT (peptide receptor radionuclide therapy) program for neuroendocrine tumors and PSMA Radioligand Therapy at UCSF.

An international leader in PET/MR research and the translation of new molecular imaging agents, Dr. Hope launched the highly successful PSMA prostate program at UCSF and championed the use of multiple new targeted therapies to treat patients with neuroendocrine and other tumors. He current serves as principal investigator on grants from the NIH, the Prostate Cancer Foundation. He is the recipient of numerous accolades in molecular imaging, including the Henkin Fellow and Marc Tetalman Memorial Award from the Society of Nuclear Medicine and Molecular Imaging, the Young Investigator Award from the Prostate Cancer Foundation and the Wylie J. Dodds Research Award from the Society of Abdominal Radiology.

Research Funding

  • July 1, 2019 - June 30, 2025 - MELT: Modulation of PSMA Expression for Lutetium Therapy , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA235741
  • March 6, 2017 - February 28, 2023 - Qualification and Harmonization of PET/MRI for Cancer Clinical Trials , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA212148
  • June 1, 2019 - April 30, 2021 - Immunogenic Priming with Lu-PSMA Targeted Therapy in Advanced Prostate Cancer , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA229354

Education

Duke University, Durham, NC, BA/BS, 6/2001, Biology, Economics
Stanford University, MD, 6/2007 Medicine
Kaiser San Francisco, 6/2008, Internal Medicine
University of California, San Francisco, 6/2012, Diagnostic Radiology Residency
Stanford University, 6/2013, Body MRI/nuclear medicine Fellowship

Honors & Awards

  • Wahl Mid-Career Leadership Award, Education and Research Foundation for Nuclear Medicine and Molecular Imaging, 2024
  • Hal O’Brien Rising Star Award Winner, Society of Nuclear Medicine and Molecular Imaging, 2020
  • Theragnostics Investigator Award, North American Neuroendocrine Tumor Society, 2018
  • Young Investigator Award, Prostate Cancer Foundation, 2017
  • Henkin Fellowship, Society of Nuclear Medicine and Molecular Imaging, 2016
  • Marc Tetalman Award, Society of Nuclear Medicine and Molecular Imaging, 2016
  • Wylie J. Dodds Research Award, Society of Abdominal Radiology, 2014
  • Roentgen Resident/Fellow Research Award, Radiological Society of North America, 2012
  • Alexander Margulis Society Outstanding Research Award, University of California, San Francisco, 2012
  • Presidents Circle Research Resident Grant, Radiological Society of North America, 2010
  • W.S. Moore Award Nominee, ISMRM, 2007
  • Trainee Research Prize, Radiological Society of North America, 2006

Selected Publications

  1. Kong G, Noe G, Chiang C, Herrmann K, Hope TA, Michael M. Assessment of response to PRRT including anatomical and molecular imaging as well as novel biomarkers. J Neuroendocrinol. 2024 Nov 09; e13461.  View on PubMed
  2. Armstrong WR, Kishan AU, Booker KM, Grogan TR, Elashoff D, Lam EC, Clark KJ, Steinberg ML, Fendler WP, Hope TA, Nickols NG, Czernin J, Calais J. Corrigendum to "Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774)" [Eur Urol. 86(1) (2024) 52-60]. Eur Urol. 2024 Nov 08.  View on PubMed
  3. Sollini M, Calais J, Chiti A, Emmett L, Fanti S, Fendler W, Herrmann K, Hope TA, Sartor O, Shuch B, Tagawa S, Hofman MS. Novel Radiopharmaceuticals and Future of Theranostics in Genitourinary Cancers. Eur Urol. 2024 Oct 19.  View on PubMed
  4. Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Zilli T, Agarwal N, Antonarakis ES, Aparicio A, Armstrong AJ, Bastos DA, Attard G, Axcrona K, Ayadi M, Beltran H, Bjartell A, Blanchard P, Bourlon MT, Briganti A, Bulbul M, Buttigliero C, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Clarke CS, Clarke N, de Bono JS, De Santis M, Duran I, Efstathiou E, Ekeke ON, El Nahas TIH, Emmett L, Fanti S, Fatiregun OA, Feng FY, Fong PCC, Fonteyne V, Fossati N, George DJ, Gleave ME, Gravis G, Halabi S, Heinrich D, Herrmann K, Hofman MS, Hope TA, Horvath LG, Hussain MHA, Jereczek-Fossa BA, Jones RJ, Joshua AM, Kanesvaran R, Keizman D, Khauli RB, Kramer G, Loeb S, Mahal BA, Maluf FC, Mateo J, Matheson D, Matikainen MP, McDermott R, McKay RR, Mehra N, Merseburger AS, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Mutambirwa SBA, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Renard-Penna R, Ryan CJ, Saad F, Sade JP, Sandhu S, Sartor OA, Schaeffer E, Scher HI, Sharifi N, Skoneczna IA, Soule HR, Spratt DE, Srinivas S, Sternberg CN, Suzuki H, Taplin ME, Thellenberg-Karlsson C, Tilki D, Türkeri LN, Uemura H, Ürün Y, Vale CL, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur Urol. 2024 Oct 10.  View on PubMed
  5. Murthy V, Voter AF, Nguyen K, Allen-Auerbach M, Chen L, Caputo S, Ledet E, Akerele A, Tuchayi AM, Lawhn-Heath C, Wang T, Carducci MA, Pomper MG, Paller CJ, Czernin J, Solnes LB, Hope TA, Sartor O, Calais J, Gafita A. Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data. J Nucl Med. 2024 Sep 26.  View on PubMed
  6. Natsuaki Y, Leynes A, Wangerin K, Hamdi M, Rajagopal A, Kinahan PE, Laforest R, Larson PEZ, Hope TA, James SS. Assessment of lesion insertion tool in pelvis PET/MR data with applications to attenuation correction method development. J Appl Clin Med Phys. 2024 Nov; 25(11):e14507.  View on PubMed
  7. Yadav S, Lowery B, Tuchayi AM, Jiang F, Saelee R, Aggarwal RR, Juarez R, Flavell RR, Hope TA. Impact of Posttreatment SPECT/CT on Patient Management During 177Lu-PSMA-617 Radiopharmaceutical Therapy. J Nucl Med. 2024 Sep 03; 65(9):1395-1401.  View on PubMed
  8. Williams H, Omer DM, Thompson HM, Lin ST, Verheij FS, Miranda J, Yuval JB, Buckley J, Marco MR, Qin LX, Dombroski DA, Kedar R, Oto A, Korngold E, Veniero JC, Gandhi S, Krishnaraj A, Jagtiani M, Ohanian K, Vu D, Hope TA, Lee S, Wasnik AP, Madhuripan N, Gollub MJ, Garcia-Aguilar J, OPRA Consortium. MRI Predicts Residual Disease and Outcomes in Watch-and-Wait Patients with Rectal Cancer. Radiology. 2024 09; 312(3):e232748.  View on PubMed
  9. Kohlbrenner R, Wu X, Nguyen HG, Cooperberg MR, Chakravarty T, Carroll PR, Hope TA. Pharmacokinetic Comparison of Selective Prostatic Arterial and Intravenous PSMA PET/CT Radioligand Infusions in Primary Prostatic Adenocarcinoma. Radiology. 2024 08; 312(2):e232544.  View on PubMed
  10. Yadav S, Jiang F, Kurkowska S, Saelee R, Morley A, Feng F, Aggarwal R, Lawhn-Heath C, Uribe C, Hope TA. Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection. J Nucl Med. 2024 Jul 01; 65(7):1064-1069.  View on PubMed
  11. Rajagopal A, Westphalen AC, Velarde N, Simko JP, Nguyen H, Hope TA, Larson PEZ, Magudia K. Mixed Supervision of Histopathology Improves Prostate Cancer Classification From MRI. IEEE Trans Med Imaging. 2024 Jul; 43(7):2610-2622.  View on PubMed
  12. Yadav S, Kim ST, Tuchayi AM, Jiang F, Morley A, Saelee R, Wang Y, Juarez R, Lawnh-Heath C, Koshkin VS, Hope TA. Comparison of 18F-DCFPyL and 68Ga-PSMA-11 for 177Lu-PSMA-617 therapy patient selection. Front Oncol. 2024; 14:1382582.  View on PubMed
  13. Kline B, Yadav S, Seo Y, Ippisch RC, Castillo J, Aggarwal RR, Kelley RK, Behr SC, Flavell RR, Lawhn-Heath C, Melisko M, Rugo HS, Wang V, Yom SS, Ha P, Jiang F, Hope TA. 68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG. J Nucl Med. 2024 Jun 03; 65(6):938-943.  View on PubMed
  14. Emmett L, Papa N, Hope TA, Fendler W, Calais J, Burger I, Eiber M, Barbato F, Moon D, Counter W, John N, Xue A, Franklin A, Thompson J, Rasiah K, Frydenberg M, Yaxley J, Buteau J, Agrawal S, Ho B, Nguyen A, Liu V, Lee J, Woo H, Hsiao E, Sutherland T, Perry E, Stricker P, Hofman MS, Kasivisvanathan V, Roberts M, Murphy D. Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer. J Urol. 2024 Aug; 212(2):299-309.  View on PubMed
  15. Nakayama M, Hope TA, Salavati A. Diagnostic and Therapeutic Application of Fibroblast Activation Protein Inhibitors in Oncologic and Nononcologic Diseases. Cancer J. 2024 May-Jun 01; 30(3):210-217.  View on PubMed
  16. Oldan JD, Almaguel F, Voter AF, Duran A, Gafita A, Pomper MG, Hope TA, Rowe SP. PSMA-Targeted Radiopharmaceuticals for Prostate Cancer Diagnosis and Therapy. Cancer J. 2024 May-Jun 01; 30(3):176-184.  View on PubMed
  17. Moradi Tuchayi A, Yadav S, Jiang F, Kim ST, Saelee RK, Morley A, Juarez R, Lawhn-Heath C, Wang Y, de Kouchkovsky I, Hope TA. Real-World Experience with 177Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval. J Nucl Med. 2024 May 01; 65(5):735-739.  View on PubMed
  18. Chauhan A, Chan K, Halfdanarson TR, Bellizzi AM, Rindi G, O'Toole D, Ge PS, Jain D, Dasari A, Anaya DA, Bergsland E, Mittra E, Wei AC, Hope TA, Kendi AT, Thomas SM, Flem S, Brierley J, Asare EA, Washington K, Shi C. Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2024 Jul-Aug; 74(4):359-367.  View on PubMed
  19. Raychaudhuri R, Mo G, Tuchayi AM, Graham L, Gulati R, Pritchard CC, Haffner MC, Yezefski T, Hawley JE, Cheng HH, Yu EY, Grivas P, Montgomery RB, Nelson PS, Chen DL, Hope T, Iravani A, Schweizer MT. Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to 177Lu-PSMA-617: A Retrospective Multicenter Cohort Study. JCO Precis Oncol. 2024 Apr; 8:e2300634.  View on PubMed
  20. Hope TA, Jadvar H. PSMA PET AUC Updates: Inclusion of rh-PSMA-7.3. J Nucl Med. 2024 Apr 01; 65(4):540.  View on PubMed

Go to UCSF Profiles, powered by CTSI